Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by foofadoooon May 11, 2017 8:44am
317 Views
Post# 26230263

Yesterday's Webinar question....

Yesterday's Webinar question....My reception was not the best at times.....However, I recall PL saying something to the effect that he was unsure the best way to describe it, he then stated (what I thought was) "it's a healing drug". M y question is....Was he refering to plasminogen by itself, in combination with PBI 4050 or was it just PBI 4050 by itself?
Also there was mention of IAIP.......so I reviewed some past NR....this one came out just prior to that New York presentation.    https://prometic.com/prometic-enters-into-strategic-agreements-with-prothera-biologics-to-develop-plasma-derived-inter-alpha-inhibitor-proteins-iaip-for-orphan-diseases/
I thought it it was worth review because it was part of the lead up before attending NY.

Just thinking about what makes these houses click......I believe it was Panmure Gordon which stated a price projection somewhere near $6.25 if Prometic was able to get any 2 indications approved.....I took that at the time as meaning maybe CKD and Alstrom. 

After a little more thought it probably meant PBI 4050 and Plasminogen...If this reasoning is good...we are probably getting very close to a breakout as our pipeline has a lot going forward...the next 3 years should be fun and won't be selling into any stink takeovers.

  foof

Bullboard Posts